Allarity Therapeutics Inc (ALLR) Actualités

Form 8-K - Current report

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

Two patients exceed 14 months on treatment in Phase 2 trial of advanced ovarian cancerAllarity maintains a...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights

  Cash balance at $18.5 millionStrengthened leadership team with new members driving stenoparib...

Form 8-K - Current report

Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib

European Patent Office to grant a patent for DRP® companion diagnostic for Allarity’s stenoparib cancer therapy...

Form 8-K - Current report

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

Boston (October 10, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a...

Form 8-K - Current report

Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program

Former Eli Lilly Research Fellow Jeremy R. Graff, Ph.D., appointed as President and Chief Development Officer...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report